Skip to main content

Table 1 Clinical characteristics of the de-escalation group and the non-de-escalation group in patients with ICU-acquired pneumoniaa

From: Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia

Characteristics De-escalation group (N= 44) Non-de-escalation group (N= 93) P value
Mean age (±SD), yr 57.45 ± 17.5 59.02 ± 15.4 0.45
Male:female ratio, n 30:14 67:26 0.64
Underlying conditions, n (%)    
   Diabetes mellitus 8 (18.2%) 14 (15.0%)  
   Structural lung disease 4 (9.1%) 9 (9.7%)  
   Renal failure (Cr >2.0 mg/dl) 4 (9.1%) 19 (20.4%)  
   Malignancy 10 (22.7%) 34 (36.6%)  
   Liver disease 4 (9.1%) 8 (8.6%)  
   Transplantation 5 (11.4%) 8 (8.6%)  
   Congestive heart failure 10 (22.7%) 15 (16.1%)  
   Postoperative state 24 (54.5%) 59 (63.4%)  
   Cerebrovascular accident 12 (27.3%) 22 (23.7%)  
   Alcoholism 1 (2.3%) 3 (3.2%)  
Prior antibiotic use, n (%) 42 (95.9%) 86 (92.5%) 0.51
Mean prior length of ICU stay (±SD), days 13.43 ± 22.7 13.39 ± 20.0 0.88
Use of MV, n (%) 39 (88.6%) 85 (91.4%) 0.60
Mean prior length of MV (±SD), days 7.6 ± 6.4 7.9 ± 9.8 0.37
Mean CCS (±SD) 2.43 ± 1.5 2.34 ± 1.5 0.66
Mean APACHE II score (±SD) 15.6 ± 5.5 15.3 ± 5.3 0.90
Mean CPIS (±SD) 8.32 ± 1.6 8.46 ± 1.3 0.06
  1. aAPACHE II, Acute Physiology and Chronic Health Evaluation II score; CCS, Charlson comorbidity index score; CPIS, Clinical Pulmonary Infection Score; Cr, creatinine; ICU, intensive care unit; MV, mechanical ventilation; SD, standard deviation.